卖什么
Genetic Medicine with Small Molecules
商业模式拆解
买家：谁掌握预算？
Biotech and pharma R&D teams (the partners page lists pharma collaborators; Chiesi Group signed a respiratory-disease deal in July 2025).
触发点：什么让他们现在购买？
Partners bring hard, previously undruggable targets that protein-centric small-molecule discovery cannot reach.
工作流：什么输入变成什么输出？
AI-native pipeline: target discovery from an atlas of 200,000+ RNA pockets, hit discovery by screening RNA-small molecule libraries, then AI-driven lead optimization.
经济账：省了什么，怎么收费？
Drug-discovery collaborations: Chiesi deal pays success-based near-term payments, future milestone payments, single-digit deferred contingent payments and commercial milestones on product sales.
渠道：怎么接触到客户？
Partnering: target validation, co-development programs, platform access/licensing (Orion, Polaris, Ara) and data licensing.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2021 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.